ARACOG TRIAL reveals patients taking hormone therapy darolutamide had less mental decline compared to men taking enzalutamide for advanced prostate cancer A new randomized Alliance Foundation Trials (AFT) clinical study found that men with advanced prostate cancer taking the hormone therapy medication darolutamide had less cognitive decline compared to men taking enzalutamide. According to results…
The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials will present a diverse portfolio of research at the 2026 ASCO Annual Meeting, taking place May 29-June 2 in Chicago, Illinois, spanning breast, gastrointestinal, genitourinary, thoracic, neuro-oncology, health outcomes, and data science. Collectively, these studies reflect the continued leadership of the Alliance in practice-changing clinical trials, translational biomarker…
At the Alliance for Clinical Trials in Oncology, we love sharing stories that show what’s happening in cancer research right now. Whether it’s a new clinical trial, a scientific breakthrough, or the work of one of our dedicated investigators, we want people to see the progress being made, and the real humans behind it. These…
The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new drug combinations for rare and aggressive cancers to evaluating digital health tools that improve access to genetic services, these trials aim to improve outcomes, reduce…
At the Alliance, we share stories highlighting the progress and impact of cancer research. By shining a light on new clinical trials, scientific discoveries, and the achievements of our investigators, we showcase the progress being made against cancer and the people driving it forward. These stories raise awareness of the essential role clinical trials play…
The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new drug combinations for rare and aggressive cancers to evaluating digital health tools that improve access to genetic services, these trials aim to improve outcomes, reduce…
Highlighting the progress and impact of cancer research, the Alliance shares stories about new clinical trials, scientific discoveries, and the achievements of our investigators. These features showcase the progress being made against cancer and the people driving it forward. By sharing these stories, we raise awareness of the vital role clinical trials play in improving…
Recent publications from Alliance investigators are delivering practice-changing insights that directly improve patient care. Featured in leading journals—including the New England Journal of Medicine, Journal of Clinical Oncology, and JAMA Oncology—these studies are shaping treatment strategies for prostate cancer, meningioma, lung cancer, and colon cancer. Below is a selection of these recent publications. Journal of…
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Published in Clinical and Translational Science, this secondary analysis of Alliance A032201 could lead to more…
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer. “Our goal in this trial is to strategically improve both survival…